LM 306
Alternative Names: LM-306Latest Information Update: 18 Sep 2023
At a glance
- Originator LaNova Medicines Limited
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioma; Malignant melanoma
Most Recent Events
- 14 Apr 2023 Preclinical trials in Glioma in China (IV), prior to April 2023
- 14 Apr 2023 Preclinical trials in Malignant melanoma in China (IV), prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Glioma and Malignant melanoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)